2024
Factors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines
2023
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C, Pittet L, Jamieson T, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Curtis N, Croda J. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers In Immunology 2023, 14: 1172851. PMID: 37465688, PMCID: PMC10352084, DOI: 10.3389/fimmu.2023.1172851.Peer-Reviewed Original ResearchConceptsRecent BCG vaccinationBCG vaccinationAntibody responseVaccine platformAnti-spike IgG responseCOVID-19 vaccinationCOVID-19 vaccineCoronaVac vaccinationPrior vaccinationVaccine responsesIgG responsesSecond doseIgG antibodiesHealthcare workersVaccinationChAdOx1CoronaVacCOVID-19VaccineMultiple factorsResponsePlaceboDoseTrialsAntibodies
2007
The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis
Silva É, Medeiros MA, McBride AJ, Matsunaga J, Esteves GS, Ramos JG, Santos CS, Croda J, Homma A, Dellagostin OA, Haake DA, Reis MG, Ko AI. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007, 25: 6277-6286. PMID: 17629368, PMCID: PMC1994161, DOI: 10.1016/j.vaccine.2007.05.053.Peer-Reviewed Original ResearchConceptsMajor public health problemRobust antibody responseGolden Syrian hamstersPublic health problemPotential intervention strategiesLethal inoculumSurface-exposed determinantsProtective immunityAntibody responseSterilizing immunityLethal infectionHamster modelVaccine candidatesSubunit vaccineCompanion animalsHealth problemsVeterinary diseasesSyrian hamstersLeptospiral immunoglobulin-like (Lig) proteinsLeptospira interrogansLeptospirosisL. interrogansIntervention strategiesVirulence factorsImmunoglobulin-like proteinLeptospira Immunoglobulin-Like Proteins as a Serodiagnostic Marker for Acute Leptospirosis
Croda J, Ramos JG, Matsunaga J, Queiroz A, Homma A, Riley LW, Haake DA, Reis MG, Ko AI. Leptospira Immunoglobulin-Like Proteins as a Serodiagnostic Marker for Acute Leptospirosis. Journal Of Clinical Microbiology 2007, 45: 1528-1534. PMID: 17360842, PMCID: PMC1865864, DOI: 10.1128/jcm.02344-06.Peer-Reviewed Original ResearchConceptsSerodiagnostic markerDays of illnessLarge disease burdenLeptospira immunoglobulin-like proteinAcute infectionClinical presentationAcute leptospirosisIgM antibodiesAntibody responseDisease burdenPutative virulence determinantsIgM enzymeTimely diagnosisSevere formHealthy individualsMicroagglutination testPatientsUrban outbreaksHigh mortalityInfectious diseasesPathogenic serovarsLeptospirosisImmunosorbent assaySerumSpecific markers